Safety and efficacy of cabazitaxel in Japanese patients with castration-resistant prostate cancer

Autor: Haruaki Kato, Kazuyoshi Iijima, Teppei Yamamoto, Tomomi Haba, Hiroshi Oike, Tomohiko Oguchi, Masashi Shiozaki, Osamu Ishizuka
Rok vydání: 2020
Předmět:
PSA-PFS
PSA progression-free survival
medicine.medical_specialty
Neutropenia
Urology
030232 urology & nephrology
Castration resistant
lcsh:RC870-923
OS
overall survival
03 medical and health sciences
Prostate cancer
0302 clinical medicine
White blood cell
Internal medicine
medicine
mCRPC
metastatic castrate-resistant prostate cancer
GS
Gleason Score
Adverse effect
Castration-resistant prostate cancer
FN
febrile neutropenia
NLR
neutrophil/lymphocyte ratio
PSA
prostate-specific antigen
Cabazitaxel
Leukopenia
business.industry
CRPC
castrate-resistant prostate cancer
lcsh:Diseases of the genitourinary system. Urology
medicine.disease
HR
hazard ratio
PS
performance status
medicine.anatomical_structure
030220 oncology & carcinogenesis
Cohort
Original Article
Safety
medicine.symptom
business
AE
adverse event
WBC
white blood cell
medicine.drug
Zdroj: Prostate International
Prostate International, Vol 8, Iss 1, Pp 27-33 (2020)
ISSN: 2287-8882
Popis: Background: Several studies have reported the efficacy of cabazitaxel in cancer therapy; however, investigations of its safety are few. The aim of this study was to retrospectively analyze the efficacy and safety of cabazitaxel based on treatment outcome data. Methods: A questionnaire form on the use of cabazitaxel was mailed to hospitals associated with the Shinshu University. Responses were received from 11 institutions regarding 55 cases. Results: Patients received a median of 4 courses of cabazitaxel treatment. Decreases in prostrate-specific antigen (PSA) were observed in 61.5% of cases with declines of 30%, 50%, and 90% in 36.5%, 23.0%, and 7.6% of cases, respectively. PSA progression-free survival was 5.0 months, and overall survival after the start of cabazitaxel was 13.0 months. Forty-five patients received postcabazitaxel treatment; 17 showed decreased PSA. Safety assessment indicated that white blood cell and neutrophil counts were significantly higher in the second than in the first course of treatment and Grade 3 to 4 leukopenia and neutropenia significantly decreased. Twenty-four subjects were aged ≥75 years; 79% of them had their doses reduced at the first administration. The mean dose was 20 mg/m2. However, there was no significant difference in the PSA progression-free survival between the ≥75-year-old and
Databáze: OpenAIRE
Externí odkaz: